Fractional Dosing of the Comirnaty Vaccine in 2 Patients With Immediate Acute Urticaria After the First Dose

Gironés, M Antón; Lacomba, J Montoro; Cascales, T Navarro; Gutarra, M. Lindo; Calle, Francisco Manuel Marco de la

doi:10.18176/jiaci.0717

“…15 Research by Anton Girones et al showed a higher prevalence rate (0.18%) but it was relatively low compared to other studies that only looked at the incidence of direct urticaria with smaller samples. 16 The study of Wentrys and Stopyra, although it also only looked at direct urticaria, had a higher prevalence rate (1.2%), probably because half of the sample in this study had a history of anaphylaxis, and the sample size of this study was the lowest. 17 Pourani et al, who had the highest prevalence (3.2%) in this review, may be due to this study not only looking at immediate urticaria but also delayed urticaria (onset of more than 4 hours).…”

Section: Discussionmentioning

confidence: 74%

“…Bianchi et al, 15 Anton Girones et al, 16 and Wentrys and Stopyra 17 described cases of urticaria in their study as having an immediate onset (onset within 4 hours). Pourani et al 18 and Grieco et al 19 stated that all cases of urticaria in their study occurred with an onset of more than 24 hours.…”

Section: Discussionmentioning

confidence: 88%

See 1 more Smart Citation

A rapid review of the prevalence and onset of urticaria triggered by COVID-19 vaccine

Oktarina

¹

,

Fadhal

²

,

Febriana

³

et al. 2022

F1000Res

0

View full text Add to dashboard Cite

Background: The Coronavirus Disease 2019 (COVID-19) vaccine is essential to reduce the spread of this disease virus and is very effective at preventing patients with severe symptoms of the disease from dying. As of February 2022, more than 10 billion doses of the COVID-19 vaccine have been administered worldwide, and at least 60% of the world's population have received the first dose of the vaccine. The increasing number of populations receiving the COVID-19 vaccine has increased reports of post-immunization follow-up events, one of which is urticaria. This study aimed to determine the prevalence and onset of urticaria due to the administration of the COVID-19 vaccine. Methods: This study used a rapid review method based on previous research on the prevalence and onset of urticaria due to the COVID-19 vaccine. The articles were obtained from the PubMed and Google Scholar databases. The inclusion criteria were articles containing data on the prevalence and onset of urticaria due to the COVID-19 vaccine, published from December 2020 – January 2022. Results: From the search results and article selection, 20 articles were included in this study. There are 7 articles containing prevalence data, 11 articles containing onset data, and 2 articles containing prevalence and onset data. Research in these articles was conducted in several different countries. There were seven types of vaccine used with doses of 1 or 2. The sample age ranged from 16 to 76 years. In all of the articles, the sample and the incidence of urticaria were mostly female. There were a history of allergies and atopic history in the sample studied. Conclusion: The prevalence rate of urticaria in the population given the COVID-19 vaccine ranged from 0.035% to 3.2%. The time of onset of urticaria in the population given the COVID-19 vaccine ranged from 5 minutes to 10 days.

show abstract

“…BBV152 has the highest prevalence, which was 5%. [15][16][17][18][19][29][30][31] Furthermore, the prevalence of urticaria with BBIBP-CorV was 2.46%, mRNA-1273 was 1.79%, ChAdOx1 nCoV-19 was 0.67%, BNT162b2 was 0.63%, and Sputnik V was 0.28%. The number of recipients of the BBV152 vaccine was the smallest, at 40.…”

Section: Discussionmentioning

confidence: 99%

A rapid review of the prevalence and onset of urticaria triggered by COVID-19 vaccine

Fadhal

¹

,

Febriana

²

,

Kusuma

³

et al. 2023

F1000Res

0

View full text Add to dashboard Cite

Background: The Coronavirus Disease 2019 (COVID-19) vaccine is essential to reduce the spread of this disease virus and is very effective at preventing patients with severe symptoms of the disease from dying. As of February 2022, more than 10 billion doses of the COVID-19 vaccine have been administered worldwide, and at least 60% of the world's population have received the first dose of the vaccine. The increasing number of populations receiving the COVID-19 vaccine has increased reports of post-immunization follow-up events, one of which is urticaria. This study aimed to determine the prevalence and onset of urticaria due to the administration of the COVID-19 vaccine. Methods: This study used a rapid review method based on previous research on the prevalence and onset of urticaria due to the COVID-19 vaccine. The articles were obtained from the PubMed and Google Scholar databases. The inclusion criteria were articles containing data on the prevalence and onset of urticaria due to the COVID-19 vaccine, published from December 2020 – January 2022. Results: From the search results and article selection, 20 articles were included in this study. There are 7 articles containing prevalence data, 11 articles containing onset data, and 2 articles containing prevalence and onset data. Research in these articles was conducted in several different countries. There were seven types of vaccine used with doses of 1 or 2. The sample age ranged from 16 to 76 years. In all of the articles, the sample and the incidence of urticaria were mostly female. There were a history of allergies and atopic history in the sample studied. Conclusion: The prevalence rate of urticaria in the population given the COVID-19 vaccine ranged from 0.035% to 3.2%. The time of onset of urticaria in the population given the COVID-19 vaccine ranged from 5 minutes to 10 days.

show abstract

Tozinameran

2022

Reactions Weekly

0

View full text Add to dashboard Cite

Fractional Dosing of the Comirnaty Vaccine in 2 Patients With Immediate Acute Urticaria After the First Dose

Cited by 3 publications

References 0 publications

A rapid review of the prevalence and onset of urticaria triggered by COVID-19 vaccine

A rapid review of the prevalence and onset of urticaria triggered by COVID-19 vaccine

A rapid review of the prevalence and onset of urticaria triggered by COVID-19 vaccine

Tozinameran

Contact Info

Product

Resources

About